Stelzer Laurie 4

What Happened
Laurie Stelzer, a director of MBX Biosciences (MBX), received a derivative equity award for 32,000 shares on January 20, 2026. The reported acquisition price is $0.00, so no cash was paid at grant. This is a compensation/award grant (not a purchase or sale) and does not represent an immediate open-market buy or sell.

Key Details

• Transaction date: 2026-01-20; filing date: 2026-01-22 (filed within the normal 2‑business‑day window).
• Shares granted: 32,000 derivative shares; reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided excerpt.
• Vesting note (from filing): One-third of the shares underlying this option will vest on Jan 20, 2027 (one-year anniversary); the remainder vests monthly over the following two years, subject to continued service.
• Transaction type code: A (award/grant); this is a derivative grant rather than an open‑market purchase.

Context
Derivative awards like this typically represent stock options, restricted stock units (RSUs), or similar awards that vest over time; until vested (and any required exercise steps completed, if applicable), the shares are generally not marketable. Grants are common as director or employee compensation and are informational rather than a direct bullish/bearish trade signal.